Universitatsklinikum Munster Klinik fur Augenheilkunde Albert-Schweitzer-Campus 1
- Address
- Gebaude D15, 48149 Munster, Germany
Universitätsklinikum Münster - Klinik für Augenheilkunde
The Department of Ophthalmology at Universitätsklinikum Münster, located at Albert-Schweitzer-Campus 1, is a specialized center dedicated to advancing treatment options for complex corneal and ocular surface disorders. The clinic participates in cutting-edge international clinical research to evaluate innovative therapeutic approaches for rare and challenging eye conditions.
- Neurotrophic keratopathy treatment and management
- Corneal disease clinical trials
- Novel ophthalmic solution therapies
The center's research portfolio includes participation in Phase 3 multi-center studies evaluating regenerative ophthalmic therapies for conditions affecting corneal integrity. Their involvement in randomized, placebo-controlled trials demonstrates a commitment to evidence-based medicine and the development of neurotrophic keratopathy treatments, a rare condition caused by corneal nerve damage that can lead to vision-threatening complications.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universitatsklinikum Munster Klinik fur Augenheilkunde Albert-Schweitzer-Campus 1
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| SEER-3: A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy | Regentree LLC | Phase III | Not Recruiting | Aug 2023 | Feb 2025 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Timbetasin Acetate | 1 | Unknown | 2023-08-29 | 2023-08-29 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.